Vector: targeted gene delivery with immune-shielded, high-capacity virus-like particles

Vector is using immune-shielded virus shells stripped of viral genes as large capacity vectors to deliver DNA-encoding therapeutics with cell and tissue specificity. The technology allows in vivo applications such as genome editing, engineering cells into CAR T cells or making cells produce encoded antibodies.

Vector BioPharma AG, which debuted Wednesday, is the latest company to emerge from Versant Ventures’ Basel-based incubator Ridgeline, which provides biologists, chemists, wet lab equipment and other infrastructure to start-ups as Versant nurses them through their infancy. The firm committed $30 million in series A funding. ...